Cost of early-stage mycosis fungoides treatments in Spain

References

• Kim EJ, Hess S, Richardson SK, et al. Immunopathogenesis and therapy of cutaneous T cell lymphoma. J Clin Invest. 2005;115(4):798–812. doi:10.1172/JCI24826
   PubMed Web of Science ®Google Scholar
• Jawed SI, Myskowski PL, Horwitz S, Moskowitz A, Querfeld C. Primary cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome). J Am Acad Dermatol. 2014;70(2):205.e1–205.e16. doi:10.1016/j.jaad.2013.07.049
   Web of Science ®Google Scholar
• Willemze R, Jaffe ES, Burg G, et al. WHO-EORTC classification for cutaneous lymphomas. Blood. 2005;105(10):3768–3785. doi:10.1182/blood-2004-09-3502
   PubMed Web of Science ®Google Scholar
• Swerdlow SH, Campo E, Pileri SA, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016;127(20):2375–2390. doi:10.1182/blood-2016-01-643569
   PubMed Web of Science ®Google Scholar
• Willemze R, Cerroni L, Kempf W, et al. The 2018 update of the WHO-EORTC classification for primary cutaneous lymphomas. Blood. 2019;133(16):1703–1714. doi:10.1182/blood-2018-11-881268
   PubMed Web of Science ®Google Scholar
• Olsen EA. Evaluation, diagnosis, and staging of cutaneous lymphoma. Dermatol Clin. 2015;33(4):643–654. doi:10.1016/j.det.2015.06.001
   PubMed Web of Science ®Google Scholar
• Wilcox RA. Cutaneous T-cell lymphoma: 2016 update on diagnosis, risk-stratification, and management. Am J Hematol. 2016;91(1):151–165. doi:10.1002/ajh.24233
   PubMed Web of Science ®Google Scholar
• Demierre M-F, Gan S, Jones J, Miller DR. Significant impact of cutaneous T-cell lymphoma on patients’ quality of life. Cancer. 2006;107(10):2504–2511. doi:10.1002/cncr.22252
   PubMed Web of Science ®Google Scholar
• Angelis A, Tordrup D, Kanavos P. Socio-economic burden of rare diseases: a systematic review of cost of illness evidence. Health Policy (New York). 2015;119(7):964–979. doi:10.1016/j.healthpol.2014.12.016
   PubMed Web of Science ®Google Scholar
• Willemze R. Cutaneous T-cell lymphoma: epidemiology, etiology, and classification. Leuk Lymphoma. 2003;44(Suppl 3):S49–S54. doi:10.1080/10428190310001623766
   Web of Science ®Google Scholar
• Trautinger F, Eder J, Assaf C, et al. European Organisation for Research and Treatment of Cancer consensus recommendations for the treatment of mycosis fungoides/Sézary syndrome – Update 2017. Eur J Cancer. 2017;77:57–74. doi:10.1016/j.ejca.2017.02.027
   PubMed Web of Science ®Google Scholar
• Orphanet. Classic mycosis fungoides. Available from: https://www.orpha.net/consor/cgi-bin/OC_Exp.php?Lng=EN&Expert=2584. Accessed November 28, 2018.
   Google Scholar
• Genetic and Rare Diseases Information Center (GARD). Mycosis fungoides. Available from: https://rarediseases.info.nih.gov/diseases/3863/mycosis-fungoides. Accessed November 19, 2018.
   Google Scholar
• Wilson LD, Hinds GA, Yu JB. Age, race, sex, stage, and incidence of cutaneous lymphoma. Clin Lymphoma Myeloma Leuk. 2012;12(5):291–296. doi:10.1016/j.clml.2012.06.010
   PubMed Web of Science ®Google Scholar
• Imam MH, Shenoy PJ, Flowers CR, Phillips A, Lechowicz MJ. Incidence and survival patterns of cutaneous T-cell lymphomas in the United States. Leuk Lymphoma. 2013;54(4):752–759. doi:10.3109/10428194.2012.729831
   PubMed Web of Science ®Google Scholar
• Bradford PT, Devesa SS, Anderson WF, Toro JR. Cutaneous lymphoma incidence patterns in the United States: a population-based study of 3884 cases. Blood. 2009;113(21):5064–5073. doi:10.1182/blood-2008-10-184168
   PubMed Web of Science ®Google Scholar
• Smith A, Crouch S, Lax S, et al. Lymphoma incidence, survival and prevalence 2004–2014: sub-type analyses from the UK’s Haematological Malignancy Research Network. Br J Cancer. 2015;112(9):1575–1584. doi:10.1038/bjc.2015.94
   PubMed Web of Science ®Google Scholar
• Estrach T, Servitje O, Ortiz-Romero PL. Registro de linfomas cutáneos primarios de la AEDV [AEDV primary cutaneous lymphoma registry]. Actas Dermosifiliogr. 2017;108(3):181–183. doi:10.1016/j.ad.2017.02.008
   Web of Science ®Google Scholar
• Quaglino P, Maule M, Prince HM, et al. Global patterns of care in advanced stage mycosis fungoides/Sezary syndrome: a multicenter retrospective follow-up study from the Cutaneous Lymphoma International Consortium. Ann Oncol. 2017;28(10):2517–2525. doi:10.1093/annonc/mdx352
   PubMed Web of Science ®Google Scholar
• Peñate Y, Servitje O, Machan S, et al. The first year of the AEVD primary cutaneous lymphoma registry. Actas Dermosifiliogr. 2018;109(7):610–616. doi:10.1016/j.ad.2018.03.006
   PubMed Web of Science ®Google Scholar
• Hwang ST, Janik JE, Jaffe ES, Wilson WH. Mycosis fungoides and Sézary syndrome. Lancet. 2008;371(9616):945–957. doi:10.1016/S0140-6736(08)60420-1
   PubMed Web of Science ®Google Scholar
• Girardi M, Heald PW, Wilson LD. The pathogenesis of mycosis fungoides. N Engl J Med. 2004;350(19):1978–1988. doi:10.1056/NEJMra032810
   PubMed Web of Science ®Google Scholar
• Kazakov D, Burg G, Kempf W. Clinicopathological spectrum of mycosis fungoides. J Eur Acad Dermatol Venereol. 2004;18(4):397–415. doi:10.1111/j.1468-3083.2004.00937.x
   Web of Science ®Google Scholar
• Olsen E, Vonderheid E, Pimpinelli N, et al. Revisions to the staging and classification of mycosis fungoides and Sézary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Ca. Blood. 2007;110(6):1713–1722. doi:10.1182/blood-2007-03-055749
   PubMed Web of Science ®Google Scholar
• Agar NS, Wedgeworth E, Crichton S, et al. Survival outcomes and prognostic factors in mycosis fungoides/sézary syndrome: validation of the revised International Society for Cutaneous Lymphomas/European Organisation for research and treatment of cancer staging proposal. J Clin Oncol. 2010;28(31):4730–4739. doi:10.1200/JCO.2009.27.7665
   PubMed Web of Science ®Google Scholar
• Quaglino P, Pimpinelli N, Berti E, et al. Time course, clinical pathways, and long-term hazards risk trends of disease progression in patients with classic mycosis fungoides: a multicenter, retrospective follow-up study from the Italian Group of Cutaneous Lymphomas. Cancer. 2012;118(23):5830–5839. doi:10.1002/cncr.27627
   PubMed Web of Science ®Google Scholar
• Kim Y, Liu H, Mraz-Gernhard S, Varghese A, Hoppe R. Long-term outcome of 525 patients with mycosis fungoides and sézary syndrome: clinical prognostic factors and risk for disease progression. Arch Dermatol. 2003;139(7):857–866. doi:10.1001/archderm.139.7.857
   PubMedGoogle Scholar
• Scarisbrick JJ, Kim YH, Whittaker SJ, et al. Prognostic factors, prognostic indices and staging in mycosis fungoides and Sézary syndrome: where are we now? Br J Dermatol. 2014;170(6):1226–1236. doi:10.1111/bjd.12909
   PubMed Web of Science ®Google Scholar
• Van Doorn R, Van Haselen C, Van Voorst Vader P, et al. Mycosis fungoides: disease evolution and prognosis of 309 dutch patients. Arch Dermatol. 2000;136(4):504–510. doi:10.1001/archderm.136.4.504
   PubMedGoogle Scholar
• Network National Comprehensive Cancer. Mycosis fungoides/sezary syndrome (guidelines Version 4.2018). 2018. Available from: https://www.nccn.org/.
   Google Scholar
• Willemze R, Hodak E, Zinzani P, Specht L, Ladetto M, Committee EG. Primary cutaneous lymphomas: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2018;29(Suppl4):iv30–iv40. doi:10.1093/annonc/mdy133
   Web of Science ®Google Scholar
• Wilcox RA. Cutaneous T-cell lymphoma: 2017 update on diagnosis, risk-stratification, and management. Am J Hematol. 2017;92(10):1085–1102. doi:10.1002/ajh.24876
   PubMed Web of Science ®Google Scholar
• Demierre MF, Olsen EA, Williams CA, Arduino JM, McNaughton KS. An in-depth assessment of the impact of pruritus on health-related quality of life of patients with mycosis fungoides/sézary syndrome. J Support Oncol. 2011;9(3):e13–e19. doi:10.1016/j.suponc.2011.02.001
   PubMedGoogle Scholar
• Hodak E, Lessin S, Friedland R, et al. New insights into associated co-morbidities in patients with cutaneous T-cell lymphoma (mycosis fungoides). Acta Derm Venereol. 2013;93(4):451–455. doi:10.2340/00015555-1496
   Web of Science ®Google Scholar
• Gu T, Raspa S, Tsang Y, Drake W. The burden of illness of mycosis fungoides cutaneous T-cell lymphoma: a retrospective cohort study of a commercially insured population in the U.S. Value Heal. 2016;19(7):A608. doi:10.1016/j.jval.2016.09.1508
   Web of Science ®Google Scholar
• Ricci E, Cortelazzo S, Krulichova I, Garattini L. Direct medical costs of mycosis fungoides in specialized Italian hospital departments. Haematologica. 2005;90(2):270–272.
   Web of Science ®Google Scholar
• Tsang Y, Gu T, Sharma G, Raspa S, Drake B, Tan H. Healthcare resource utilization, costs of care, and treatment of mycosis fungoides cutaneous T-cell lymphoma patterns in a large managed care population: a retrospective US claims-based analysis. J Dermatolog Treat. 2018;29(8):747–753. doi:10.1080/09546634.2018.1466026
   PubMed Web of Science ®Google Scholar
• Cameron H, Yule S, Dawe RS, Ibbotson SH, Moseley H, Ferguson J. Review of an established UK home phototherapy service 1998–2011: improving access to a cost-effective treatment for chronic skin disease. Public Health. 2014;128(4):317–324. doi:10.1016/j.puhe.2014.01.011
   Web of Science ®Google Scholar
• Ministerio de Sanidad Consumo y Bienestar Social. Listado de Medicamentos Afectados Por Las Deducciones Del Real Decreto-Ley 8/2010 Noviembre 2018 [Medicines List Affected by the Royal Decree-Law 8/2010 November Deduction]. Madrid; 2018. Available from: https://www.mscbs.gob.es/en/profesionales/farmacia/notasInfor.htm.
   Google Scholar
• Bot PLUS: Base de Datos de Información Sanitaria [Bot PLUS: health information database]. Available from: https://botplusweb.portalfarma.com/botplus.aspx. Published 2019. Accessed July 19, 2019.
   Google Scholar
• Oblikue Consulting SL. Spanish Health Costs Database: eSalud. Barcelona: Oblikue Consulting SL; 2018. Available from http://oblikue.com/bddcostes. Accessed July 19, 2019.
   Google Scholar
• Nolla JM, Martín E, Llamas P, et al. An estimate of the cost of administering intravenous biological agents in Spanish day hospitals. Ther Clin Risk Manag. 2017;13:325–334. doi:10.2147/TCRM.S112062
   PubMed Web of Science ®Google Scholar
• Alfageme Roldán F, Bermejo Hernando A, Calvo González JL, Marqués Sánchez P. Coste efectividad de diferentes tratamientos para la psoriasis [Cost effectiveness of treatments of psoriasis]. Rev Esp Salud Pública. 2016;90:e1–e7.
   Google Scholar
• Berlana D, Sabin P, Gimeno-Ballester V, et al. Cost analysis of adult parenteral nutrition systems; three-compartment bag versus customized. Nutr Hosp. 2013;28(6):2135–2141. doi:10.3305/nh.2013.28.6.6862
   Web of Science ®Google Scholar
• Comunidad de Madrid (Atención Primaria Área 11). Publicación en el portal de la contratación pública PA/TA/AB/11/08/SU/10, de la Comunidad de Madrid [Publication on the public procurement portal, Community of Madrid].
   Google Scholar
• Comunidad de Madrid. Pliego de prescripciones técnicas. Concurso suministro C. SUM 212/10 Material sanitario (agujas y jeringas). 2010 [Technical specifications document. Supply contract C. SUM 212/10 sanitary material (needles and syringes). 2010].
   Google Scholar
• Gobierno de Aragón (Servicio Aragonés de Salud). Pliego-tipo cláusulas administrativas. Concursos de bienes con destino a centros dependientes del Servicio Aragonés de Salud. 2006 [Specification-type administrative clauses. Tenders destined to centers of the Aragon Health Service. 2006].
   Google Scholar
• National Statistics Institute. National Health Survey: 2017. Madrid: National Statistics Institute; 2017.
   Google Scholar
• Heald P, Mehlmauer M, Martin AG, et al. Topical bexarotene therapy for patients with refractory or persistent early-stage cutaneous T-cell lymphoma: results of the Phase III clinical trial. J Am Acad Dermatol. 2003;49(5):801–815. doi:10.1016/S0190-9622(03)01475-0
   PubMed Web of Science ®Google Scholar
• Committee for Medicinal Products for Human Use. European Public Assessment Report: LEDAGA (EMA/CHMP/13156/2017). Amsterdam; 2017.
   Google Scholar
• Dávila C, Clérigues MN. Farmacotecnia: boletín informativo [Pharmacotechnics: newsletter]. Farmacotecnia. 2012;2(3):1–13. Available from: https://www.sefh.es/sefhpublicaciones/boletines-farmacotecnia/boletin-septiembre-diciembre-2012.pdf Published 2012. Accessed November 28, 2018.
   Google Scholar
• Grupo de trabajo de Farmacotecnia de la Sociedad Española de Farmacia Hospitalaria. Información Lista Sociedad Española de Farmacia Hospitalaria. 2018. [Information list of the Spanish Society of Hospital Pharmacy. 2018].
   Google Scholar
• Hospital Universitario 12 de Octubre (Servicio de Farmacia). Preparación de Medicamentos: Formulación Magistral. Volumen I [Drug Preparation: Master Formulation. Volume I]. Madrid: Hospital Universitario 12 de Octubre; 2010.
   Google Scholar
• Zackheim HS, Epstein EH, Crain WR. Topical carmustine (BCNU) for cutaneous T cell lymphoma: a 15-year experience in 143 patients. J Am Acad Dermatol. 1990;22(5):802–810. doi:10.1016/0190-9622(90)70112-U
   Web of Science ®Google Scholar
• British Columbia Cancer Drug Manual. Carmustine Monograph. Vancouver: Provincial Health Services Authority (PHSA); 2018. Available from: http://www.bccancer.bc.ca/health-professionals/clinical-resources/cancer-drug-manual/drug-index#c-content. Published 2018. Accessed November 28, 2018.
   Google Scholar
• Hernández Z, Peñate Y, Hernández-Machín B, et al. Treatment of stage Ia and Ib mycosis fungoides with psoralen UVA monotherapy: an observational study in tertiary hospitals in the Canary Islands. Int J Dermatol. 2014;53(11):1417–1422. doi:10.1111/ijd.12425
   PubMed Web of Science ®Google Scholar
• Martín Gutiérrez F, Ortega Resinas M, Camacho Martínez F. Fototerapia UVB en la micosis fungoide [UVB phototherapy in mycosis fungoides]. Actas Dermosifiliogr. 2000;91(3):98–100.
   Google Scholar
• Herrmann JJ, Roenigk HH, Hurria A, et al. Treatment of mycosis fungoides with photochemotherapy (PUVA): long-term follow-up. J Am Acad Dermatol. 1995;33(2):234–242. doi:10.1016/0190-9622(95)90241-4
   Web of Science ®Google Scholar
• Ponte P, Serrão V, Apetato M. Efficacy of narrowband UVB vs. PUVA in patients with early-stage mycosis fungoides. J Eur Acad Dermatology Venereol. 2010;24(6):716–721. doi:10.1111/j.1468-3083.2009.03500.x
   Web of Science ®Google Scholar
• Pavlotsky F, Barzilai A, Kasem R, Shpiro D, Trau H. UVB in the management of early stage mycosis fungoides. J Eur Acad Dermatology Venereol. 2006;20(5):565–572. doi:10.1111/j.1468-3083.2006.01557.x
   Web of Science ®Google Scholar
• Brazzelli V, Antoninetti M, Palazzini S, Prestinari F, Borroni G. Narrow-band ultraviolet therapy in early-stage mycosis fungoides: study on 20 patients. Photodermatol Photoimmunol Photomed. 2007;23(6):229–233. doi:10.1111/j.1600-0781.2007.00314.x
   Web of Science ®Google Scholar
• Navi D, Riaz N, Levin Y, Sullivan N, Kim Y, Hoppe R. The Stanford University experience with conventional-dose, total skin electron-beam therapy in the treatment of generalized patch or plaque (t2) and tumor (t3) mycosis fungoides. Arch Dermatol. 2011;147(5):561–567. doi:10.1001/archdermatol.2011.98
   PubMedGoogle Scholar
• Quirós PA, Jones GW, Kacinski BM, et al. Total skin electron beam therapy followed by adjuvant psoralen/ultraviolet-A light in the management of patients with T1 and T2 cutaneous T-cell lymphoma (mycosis fungoides). Int J Radiat Oncol Biol Phys. 1997;38(5):1027–1035. doi:10.1016/S0360-3016(97)00127-2
   Web of Science ®Google Scholar
• Jones GW, Tadros A, Hodson DI, Rosenthal D, Roberts J, Thorson B. Prognosis with newly diagnosed mycosis fungoides after total skin electron radiation of 30 or 35 GY. Int J Radiat Oncol Biol Phys. 1994;28(4):839–845. doi:10.1016/0360-3016(94)90103-1
   Web of Science ®Google Scholar
• Elsayad K, Kriz J, Moustakis C, et al. Total skin electron beam for primary cutaneous T-cell lymphoma. Int J Radiat Oncol Biol Phys. 2015;93(5):1077–1086. doi:10.1016/j.ijrobp.2015.08.041
   PubMed Web of Science ®Google Scholar
• Kamstrup MR, Gniadecki R, Iversen L, et al. Low-dose (10-Gy) total skin electron beam therapy for cutaneous T-cell lymphoma: an open clinical study and pooled data analysis. Int J Radiat Oncol Biol Phys. 2015;92(1):138–143. doi:10.1016/j.ijrobp.2015.01.047
   PubMed Web of Science ®Google Scholar
• Hoppe RT, Harrison C, Tavallaee M, et al. Low-dose total skin electron beam therapy as an effective modality to reduce disease burden in patients with mycosis fungoides: results of a pooled analysis from 3 phase-II clinical trials. J Am Acad Dermatol. 2015;72(2):286–292. doi:10.1016/j.jaad.2014.10.014
   PubMed Web of Science ®Google Scholar
• Zackheim H, Kashani-Sabet M, Amin S. Topical corticosteroids for mycosis fungoides: experience in 79 patients. Arch Dermatol. 1998;134(8):949–954. doi:10.1001/archderm.134.8.949
   PubMed Web of Science ®Google Scholar
• Zackheim HS. Treatment of patch-stage mycosis fungoides with topical corticosteroids. Dermatol Ther. 2003;16(4):283–287. doi:10.1111/j.1396-0296.2003.01639.x
   PubMedGoogle Scholar
• Centro de información online de medicamentos (Aemps - CIMA) [Medicine online information center of AEMPS - CIMA]. Ministerio de Sanidad Consumo y Bienestar Social. Available from: https://cima.aemps.es. Published 2018. Accessed November 22, 2018.
   Google Scholar
• Andía AA. Corticoides tópicos [Topical corticosteroids]. Boletín Inf Farmacoter Navarra. 2001;9(2):1–13.
   Google Scholar
• Abbott RA, Whittaker SJ, Morris SL, et al. Bexarotene therapy for mycosis fungoides and Sézary syndrome. Br J Dermatol. 2009;160(6):1299–1307. doi:10.1111/j.1365-2133.2009.09037.x
   PubMed Web of Science ®Google Scholar
• Molin L, Thomsen K, Volden G, et al. Oral retinoids in mycosis fungoides and Sézary syndrome: a comparison of isotretinoin and etretinate. A study from the Scandinavian Mycosis Fungoides Group. Acta Derm Venereol. 1987;67(3):232–236.
   PubMed Web of Science ®Google Scholar
• Molin S, Ruzicka T. Possible benefit of oral alitretinoin in T-lymphoproliferative diseases: a report of two patients with palmoplantar hyperkeratotic-rhagadiform skin changes and mycosis fungoides or Sézary syndrome. Br J Dermatol. 2009;161(6):1420–1422. doi:10.1111/j.1365-2133.2009.09475.x
   Web of Science ®Google Scholar
• Sokołowska-Wojdyło M, Lugowska-Umer H, Maciejewska-Radomska A. Oral retinoids and rexinoids in cutaneous T-cell lymphomas. Postepy Dermatol Alergol. 2013;30(1):19–29. doi:10.5114/pdia.2013.33375
   PubMed Web of Science ®Google Scholar
• Whittaker S, Ortiz P, Dummer R, et al. Efficacy and safety of bexarotene combined with psoralen–ultraviolet A (PUVA) compared with PUVA treatment alone in stage IB–IIA mycosis fungoides: final results from the EORTC Cutaneous Lymphoma Task Force phase III randomized clinical trial. Br J Dermatol. 2012;167(3):678–687. doi:10.1111/j.1365-2133.2012.11156.x
   PubMed Web of Science ®Google Scholar
• Wozniak MB, Tracey L, Ortiz-Romero PL, et al. Psoralen plus ultraviolet A ± interferon-α treatment resistance in mycosis fungoides: the role of tumour microenvironment, nuclear transcription factor-κB and T-cell receptor pathways. Br J Dermatol. 2009;160(1):92–102. doi:10.1111/j.1365-2133.2008.08886.x
   PubMed Web of Science ®Google Scholar
• Rupoli S, Barulli S, Guiducci B, et al. Low dose interferon-alpha2b combined with PUVA is an effective treatment of early stage mycosis fungoides: results of a multicenter study. Cutaneous-T Cell Lymphoma Multicenter Study Group. Haematologica. 1999;84(9):809–813.
   Web of Science ®Google Scholar
• Rupoli S, Goteri G, Pulini S, et al. Long-term experience with low-dose interferon-α and PUVA in the management of early mycosis fungoides. Eur J Haematol. 2005;75(2):136–145. doi:10.1111/j.1600-0609.2005.00497.x
   PubMed Web of Science ®Google Scholar
• Hengge UR, Ruzicka T, Schwartz RA, Cork MJ. Adverse effects of topical glucocorticosteroids. J Am Acad Dermatol. 2006;54(1):1–15. doi:10.1016/j.jaad.2005.01.010
   PubMed Web of Science ®Google Scholar